Literature DB >> 1932300

Immunoglobulin serum levels in very low birth weight infants treated with different intravenous preparations.

M Amato1, D Markus, P Hüppi, P Imbach.   

Abstract

Parenteral human immunoglobulin (IVIG) administration is widely used in low birth weight (LBW) infants for prevention and therapy of neonatal infection. In previous studies, IVIG preparations containing IgG and low IgM concentrations were commonly used. In this study we compare immunoglobulin serum levels in two groups of healthy preterm infants receiving prophylactically standard IVIG (Sandoglobulin, 0.1 mg/kg IgM) or IgM-enriched IVIG (Pentaglobin, 30 mg/kg IgM). Immunoglobulin levels were assayed by rate nephelometry at birth and at 3, 5, 7, and 14 days after birth. The two groups of patients were matched for gestational age (31 +/- 2.3 weeks), birth weight (1320 +/- 340 g), and serum IgG (4.1 +/- 1.9 milligram) and IgM (0.22 +/- 0.18 milligram) levels at birth. Significantly higher IgM levels were observed at 3 and 5 days after IgM-enriched IVIG administration (p less than 0.01). Higher IgG levels were attained and persisted for 2 weeks after standard IVIG administration (p less than 0.01). These data indicate different IgG and IgM target levels in LBW infants treated with different immunoglobulin preparations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1932300     DOI: 10.1007/bf01703445

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  22 in total

1.  Intravenous immunoglobulin for prevention of sepsis in preterm and low birth weight infants.

Authors:  K N Haque; M H Zaidi; S K Haque; H Bahakim; M el-Hazmi; M el-Swailam
Journal:  Pediatr Infect Dis       Date:  1986 Nov-Dec

2.  Natural killer cell activity in preterm infants: effect of intravenous immune globulin administration.

Authors:  G Chirico; R Maccario; D Montagna; A Chiara; A Gasparoni; G Rondini
Journal:  J Pediatr       Date:  1990-09       Impact factor: 4.406

3.  Differences among available immunoglobulin preparations for intravenous use.

Authors:  F Skvaril; A Gardi
Journal:  Pediatr Infect Dis J       Date:  1988-05       Impact factor: 2.129

4.  Dosage of intravenously administered immune globulin and dosing interval required to maintain target levels of immunoglobulin G in low birth weight infants.

Authors:  K S Kyllonen; D W Clapp; R M Kliegman; J E Baley; N Shenker; A A Fanaroff; M Berger
Journal:  J Pediatr       Date:  1989-12       Impact factor: 4.406

Review 5.  The current status of intravenous gamma-globulin use in neonates.

Authors:  L A Gonzalez; H R Hill
Journal:  Pediatr Infect Dis J       Date:  1989-05       Impact factor: 2.129

6.  Serum gamma-G-globulin levels and gestational age in premature babies.

Authors:  J R Hobbs; J A Davis
Journal:  Lancet       Date:  1967-04-08       Impact factor: 79.321

7.  Pharmacokinetics of intravenous immunoglobulin (Sandoglobulin) in neonates.

Authors:  L E Weisman; G W Fischer; V G Hemming; C C Peck
Journal:  Pediatr Infect Dis       Date:  1986 May-Jun

8.  Immunoglobulin profile of the preterm baby.

Authors:  S P Conway; P R Dear; I Smith
Journal:  Arch Dis Child       Date:  1985-03       Impact factor: 3.791

9.  High intravenous doses of human immune globulin suppress neonatal group B streptococcal immunity in rats.

Authors:  L E Weisman; P M Lorenzetti
Journal:  J Pediatr       Date:  1989-09       Impact factor: 4.406

10.  Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: report of a pilot study.

Authors:  D W Clapp; R M Kliegman; J E Baley; N Shenker; K Kyllonen; A A Fanaroff; M Berger
Journal:  J Pediatr       Date:  1989-12       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.